Overview

PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation

Status:
Completed

Trial end date:
2009-11-01

Target enrollment:

Participant gender:

Summary

This pilot study was designed in order to evaluate the safety and efficacy of an AmBisome® loading dose regimen, in a weekly administration schedule during the initial phase of allogeneic stem-cell transplant and in case of occurrence of graft versus host disease (GvHD), which are both high risk periods as far as severe fungal infection development is concerned.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Amphotericin B
Antifungal Agents
Liposomal amphotericin B
Miconazole